Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients

Frontiers in Physiology

Volumn 9, Issue , 2018, Pages

  Uthman, Laween ^a   Baartscheer, Antonius ^a   Schumacher, Cees A ^a   Fiolet, Jan W T ^a   Kuschma, Marius C ^a   Hollmann, Markus W ^a   Coronel, Ruben ^a,b   Weber, Nina C ^a   Zuurbier, Coert J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

2 type diabetes; cardiac fibroblast; cardiomyocyte; endothelial cell; heart failure; isolated heart; SGLT2 inhibitors; smooth muscle cell

Indexed keywords

EID: 85063719532     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2018.01575     Document Type: Review

References (112)

1. Andreadou I., Efentakis P., Balafas E., Togliatto G., Davos C. H., Varela A., et al. (2017). Empagliflozin limits myocardial infarction in vivo and cell death in vitro: role of STAT3, mitochondria, and redox aspects. Front. Physiol. 8:1077. 10.3389/fphys.2017.01077 29311992
2. Azcutia V., Abu-Taha M., Romacho T., Vázquez-Bella M., Matesanz N., Luscinskas F. W., et al. (2010). Inflammation determines the pro-adhesive properties of high extracellular D-glucose in human endothelial cells in vitro and rat microvessels in vivo. PLoS One 5:e10091. 10.1371/journal.pone.0010091 20386708
3. +-exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodelling. Br. J. Pharmacol. 154 1266–1275. 10.1038/bjp.2008.189 18493245
4. +-exchanger in heart. Cardiovasc. Res. 57 986–995. 10.1016/S0008-6363(02)00848-9
5. +]I and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model. Heart Fail. 57 1015–1024. 10.1016/S0008-6363(02)00809-X
6. Baartscheer A., Schumacher C. A., Belterman C. N. W., Coronel R., Fiolet J. W. T., (2003c). S R calcium handling and calcium after-transients in a rabbit model of heart failure. Heart Fail. 58 99–108. 10.1016/S0008-6363(02)00854-4
7. +-exchanger attenuates cardiac hypertrophy and prevents cellular remodeling in heart failure. Cardiovasc. Res. 65 83–92. 10.1016/j.cardiores.2004.09.024 15621036
8. + exchanger in rats and rabbits. Diabetologia 60 568–573. 10.1007/s00125-016-4134-x 27752710
9. Baartscheer A., Van Borren M. M., (2008). Sodium ion transporters as new therapeutic targets in heart failure. Cardiovasc. Hematol. Agents Med. Chem. 6 229–236. 10.2174/187152508785909546
10. Banerjee S. K., McGaffin K. R., Pastor-Soler N. M., Ahmad F., (2009). SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc. Res. 84 111–118. 10.1093/cvr/cvp190 19509029
11. + and cardiac metabolism. J. Mol. Cell. Cardiol. 61 20–27. 10.1016/j.yjmcc.2013.05.010 23727097
12. Beauloye C., Bertrand L., Horman S., Hue L., (2011). AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc. Res. 90 224–233. 10.1093/cvr/cvr034 21285292
13. Beer M., Seyfarth T., Sandstede J., Landschütz W., Lipke C., Köstler H., et al. (2002). Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with 31P-SLOOP magnetic resonance spectroscopy. J. Am. Coll. Cardiol. 40 1267–1274. 10.1016/S0735-1097(02)02160-5 12383574
14. Bers D. M., (2014). Cardiac sarcoplasmic reticulum calcium leak: basis and roles in cardiac dysfunction. Annu. Rev. Physiol. 76 107–127. 10.1146/annurev-physiol-020911-153308 24245942
15. Bertero E., Maack C., (2018). Calcium signaling and reactive oxygen species in Mitochondria. Circ. Res. 122 1460–1478. 10.1161/CIRCRESAHA.118.310082 29748369
16. Boudina S., Sena S., Theobald H., Sheng X., Wright J. J., Hu X. X., et al. (2007). Mitochondrial energetics in the heart in obesity-related. Diabetes 56 2457–2466. 10.2337/db07-0481.Additional 17623815
17. Bugger H., Abel E. D., (2014). Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 57 660–671. 10.1007/s00125-014-3171-6 24477973
18. Byrne N. J., Parajuli N., Levasseur J. L., Boisvenue J., Beker D. L., Masson G., et al. (2017). Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. JACC Basic Transl. Sci. 2 347–354. 10.1016/j.jacbts.2017.07.003 30062155
19. Cassidy S., Hallsworth K., Thoma C., MacGowan G. A., Hollingsworth K. G., Day C. P., et al. (2015). Cardiac structure and function are altered in type 2 diabetes and Non-alcoholic fatty liver disease and associate with glycemic control. Cardiovasc. Diabetol. 14:23. 10.1186/s12933-015-0187-2 25849783
20. Cavender M. A., Steg P. G., Smith S. C., Eagle K., Ohman E. M., Goto S., et al. (2015). Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the reduction of atherothrombosis for continued health (REACH) registry. Circulation 132 923–931. 10.1161/CIRCULATIONAHA.114.014796 26152709
21. Chen S., Khan Z. A., Karmazyn M., Chakrabarti S., (2007). Role of endothelin-1, sodium hydrogen exchanger-1 and mitogen activated protein kinase (MAPK) activation in glucose-induced cardiomyocyte hypertrophy. Diabetes Metab. Res. Rev. 23 356–367. 10.1002/dmrr.689 17024690
22. Cordero M. D., Williams M. R., Ryffel B., (2018). AMP-activated protein kinase regulation of the NLRP3 inflammasome during aging. Trends Endocrinol. Metab. 29 8–17. 10.1016/j.tem.2017.10.009 29150317
23. Coronel R., Wilders R., Verkerk A. O., Wiegerinck R. F., Benoist D., Bernus O., (2013). Electrophysiological changes in heart failure and their implications for arrhythmogenesis. Biochim. Biophys. Acta 1832 2432–2441. 10.1016/j.bbadis.2013.04.002 23579069
24. Cubbon R. M., Adams B., Rajwani A., Mercer B. N., Patel P. A., Gherardi G., et al. (2013). Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology. Diabetes Vasc. Dis. Res. 10 330–336. 10.1177/1479164112471064 23349368
25. Cui G. M., Zhao Y. X., Zhang N. N., Liu Z. S., Sun W. C., Peng Q. S., (2013). Amiloride attenuates lipopolysaccharide-accelerated atherosclerosis via inhibition of NHE1-dependent endothelial cell apoptosis. Acta Pharmacol. Sin. 34 231–238. 10.1038/aps.2012.155 23274414
26. + exchanger contributes to left ventricular hypertrophy in the Goto-Kakizaki rat model of type 2 diabetes: critical role of Akt. Diabetologia 50 1335–1344. 10.1007/s00125-007-0628-x 17429605
27. +]I dysregulation in heart failure and diabetic cardiomyopathy. Front. Physiol. 9:1303. 10.3389/fphys.2018.01303
28. + concentration is elevated in heart failure but Na/K pump function is unchanged. Circulation 105 2543–2548. 10.1161/01.CIR.0000016701.85760.97
29. + release in cardiac myocytes. Cardiovasc. Res. 95 480–486. 10.1093/cvr/cvs213 22739122
30. Dey S., DeMazumder D., Sidor A., Foster D. B., O’Rourke B., (2018). Mitochondrial ROS drive sudden cardiac death and chronic proteome remodeling in heart failurenovelty and significance. Circ. Res. 123 356–371. 10.1161/CIRCRESAHA.118.312708 29898892
31. Di Franco A., Cantini G., Tani A., Coppini R., Zecchi-Orlandini S., Raimondi L., et al. (2017). Sodium-dependent glucose transporters (SGLT) in human ischemic heart: a new potential pharmacological target. Int. J. Cardiol. 243 86–90. 10.1016/j.ijcard.2017.05.032 28526540
32. Dmitrieva N. I., Burg M. B., (2015). Elevated sodium and dehydration stimulate inflammatory signaling in endothelial cells and promote atherosclerosis. PLoS One 10:e0128870. 10.1371/journal.pone.0128870 26042828
33. El Messaoudi S., Nederlof R., Zuurbier C. J., van Swieten H. A., Pickkers P., Noyez L., et al. (2015). Effect of metformin pretreatment on myocardial injury during coronary artery bypass surgery in patients without diabetes (MetCAB): a double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 3 615–623. 10.1016/S2213-8587(15)00121-7 26179504
34. El-daly M., Krishna V., Venu P., Mihara K., Kang S., Fedak P. W. M., et al. (2018). Hyperglycaemic impairment of PAR2-mediated vasodilation: prevention by inhibition of aortic endothelial sodium-glucose-co- Transporter-2 and minimizing oxidative stress. Vascul. Pharmacol. 109 56–71. 10.1016/j.vph.2018.06.006 29908295
35. + exchange prevents hypertrophy, fibrosis, and heart failure in beta1-adrenergic receptor transgenic mice. Circ. Res. 90 814–819. 10.1161/01.RES.0000014966.97486.C0
36. Erickson J. R., Pereira L., Wang L., Han G., Ferguson A., Dao K., et al. (2013). Diabetic hyperglycemia activates CaMKII and arrhythmias by O linked glycosylation. Nature 502 372–376. 10.1038/nature12537.Diabetic 24077098
37. Feldstein C. A., (2002). Salt intake and hypertension therapy. J. Hum. Hypertens. 16 48–51. 10.1038/sj/jhh/1001342
38. Ferrannini G., Hach T., Crowe S., Sanghvi A., Hall K. D., Ferrannini E., (2015). Energy balance after sodium–glucose cotransporter 2 inhibition. Diabetes Care 38 1730–1735. 10.2337/dc15-0355 26180105
39. Foretz M., Guigas B., Berbrand L., Pollak M., Viollet B., (2014). Metformin: from mechanisms of action to therapies. Cell Metab. 20 953–966. 10.1016/j.cmet.2014.09.018 25456737
40. Frati G., Schirone L., Chimenti I., Yee D., Biondi-Zoccai G., Volpe M., et al. (2017). An overview of the inflammatory signalling mechanisms in themyocardiumunderlying the development of diabetic cardiomyopathy. Cardiovasc. Res. 113 378–388. 10.1093/cvr/cvx011 28395009
41. Garcia-Dorado D., Ruiz-Meana M., Inserte J., Rodriguez-Sinovas A., Piper H. M., (2012). Calcium-mediated cell death during myocardial reperfusion. Cardiovasc. Res. 94 168–180. 10.1093/cvr/cvs116 22499772
42. Gaspari T., Spizzo I., Liu H., Hu Y., Simpson R. W., Widdop R. E., et al. (2017). Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: a potential mechanism for inhibition of atherogenesis. Diabetes Vasc. Dis. Res. 15 64–73. 10.1177/1479164117733626 29923421
43. Gélinas R., Mailleux F., Dontaine J., Bultot L., Demeulder B., Ginion A., et al. (2018). AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation. Nat. Commun. 9:374. 10.1038/s41467-017-02795-4 29371602
44. + in the regulation of cellular energetics. Biochemistry 51 2959–2973. 10.1021/bi2018909 22443365
45. + transient in ventricular myocytes from streptozotocin-induced diabetic rats. Mol. Cell. Biochem. 400 57–68. 10.1007/s11010-014-2262-5 25351341
46. Han Y., Cho Y.-E., Ayon R., Guo R., Youssef K. D., Pan M., et al. (2015). SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery. Am. J. Physiol. Lung Cell. Mol. Physiol. 309 L1027–L1036. 10.1152/ajplung.00167.2015 26361875
47. +/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes Metab. Res. Rev. 65 2784–2794. 10.2337/db16-0058 27381369
48. He C., Li H., Viollet B., Zou M. H., Xie Z., (2015). AMPK suppresses vascular inflammation in vivo by inhibiting signal transducer and activator of transcription-1. Diabetes Metab. Res. Rev. 64 4285–4297. 10.2337/db15-0107 25858560
49. He F. J., MacGregor G. A., (2018). Role of salt intake in prevention of cardiovascular disease: controversies and challenges. Nat. Rev. Cardiol. 15 371–377. 10.1038/s41569-018-0004-1 29713009
50. Ingwall J. S., (2009). Energy metabolism in heart failure and remodelling. Cardiovasc. Res. 81 412–419. 10.1093/cvr/cvn301 18987051
51. Janse M. J., Vermeulen J. T., Opthof T., Coronel R., Wilms-Schopman F. J., Rademaker H. M. E., et al. (2001). Arrhythmogenesis in heart failure. J. Cardiovasc. Electrophysiol. 12 496–499. 10.1046/j.1540-8167.2001.00496.x
52. Jespersen N. R., Lassen T. R., Hjortbak M. V., Stottrup N. B., Botker H. E., (2017). Sodium glucose transporter 2 (SGLT2) inhibition does not protect the myocardium from acute ischemic reperfusion injury but modulates post- ischemic mitochondrial function. Cardiovasc. Pharmacol. Open Access. 6 2–4. 10.4172/2329-6607.1000210
53. Jia G., Hill M. A., Sowers J. R., (2018). Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ. Res. 122 624–638. 10.1161/CIRCRESAHA.117.311586 29449364
54. Joshi M., Kotha S. R., Malireddy S., Selvaraju V., Satoskar A. R., Palesty A., et al. (2014). Conundrum of pathogenesis of diabetic cardiomyopathy: role of vascular endothelial dysfunction, reactive oxygen species, and mitochondria. Mol. Cell. Biochem. 386 233–249. 10.1007/s11010-013-1861-x 24307101
55. Kannel W. B., Hjortland M., Castelli W. P., (1974). Role of diabetes in congestive heart failure: the Framingham study. Am. J. Cardiol. 34 29–34. 10.1016/0002-9149(74)90089-7
56. Karmazyn M., (2013). NHE-1: still a viable therapeutic target. J. Mol. Cell. Cardiol. 61 77–82. 10.1016/j.yjmcc.2013.02.006 23429008
57. Kashiwagi Y., Nagoshi T., Yoshino T., Tanaka T. D., Ito K., Harada T., et al. (2015). Expression of SGLT1 in human hearts and impairment of cardiac glucose uptake by phlorizin during ischemia-reperfusion injury in mice. PLoS One 10:e0130605. 10.1371/journal.pone.0130605 26121582
58. Kasichayanula S., Liu X., Zhang W., Pfister M., Reele S. B., Aubry A. F., et al. (2011). Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects. Diabetes Obes. Metab. 13 770–773. 10.1111/j.1463-1326.2011.01397.x 21435141
59. + exchange inhibition reduces hypertrophy and heart failure after myocardial infarction in rats. Am. J. Physiol. Hear. Circ. Physiol. 280 H738–H745. 10.1152/ajpheart.2001.280.2.H738 11158973
60. +-glucose cotransport. J. Am. Heart Assoc. 4 1–11. 10.1161/JAHA.115.002183 26316524
61. Lanaspa M. A., Kuwabara M., Andres-Hernando A., Li N., Cicerchi C., Jensen T., et al. (2018). High salt intake causes leptin resistance and obesity in mice by stimulating endogenous fructose production and metabolism. Proc. Natl. Acad. Sci. U.S.A. 115:201713837. 10.1073/pnas.1713837115 29507217
62. Lastra G., Dhuper S., Johnson M. S., Sowers J. R., (2010). Salt, aldosterone, and insulin resistance: impact on the cardiovascular system. Nat. Rev. Cardiol. 7 577–584. 10.1038/nrcardio.2010.123 20697411
63. Lee T. M., Chang N. C., Lin S. Z., (2017). Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic. Biol. Med. 104 298–310. 10.1016/j.freeradbiomed.2017.01.035 28132924
64. Levelt E., Rodgers C. T., Clarke W. T., Mahmod M., Ariga R., Francis J. M., et al. (2016). Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus. Eur. Heart J. 37 3461–3469. 10.1093/eurheartj/ehv442 26392437
65. Li C.-Y., Wang L.-X., Dong S.-S., Hong Y., Zhou X.-H., Zheng W.-W., et al. (2018). Phlorizin exerts direct protective effects on palmitic acid (PA)-induced endothelial dysfunction by activating the PI3K/AKT/eNOS signaling pathway and increasing the levels of nitric oxide (NO). Med. Sci. Monit. Basic Res. 24 1–9. 10.12659/MSMBR.907775 29307883
66. Li J., Wang Y., Wang Y., Wen X., Ma X. N., Chen W., et al. (2015). Pharmacological activation of AMPK prevents Drp1-mediated mitochondrial fission and alleviates endoplasmic reticulum stress-associated endothelial dysfunction. J. Mol. Cell. Cardiol. 86 62–74. 10.1016/j.yjmcc.2015.07.010 26196303
67. + uptake in myocytes from failing hearts restores energy supply and demand matching. Circ. Res. 103 279–288. 10.1161/CIRCRESAHA.108.175919 18599868
68. Luo M., Guan X., Luczak E. D., Lang D., Kutschke W., Gao Z., et al. (2013). Diabetes increases mortality after myocardial infarction by oxidizing CaMKII. J. Clin. Invest. 123 1262–1274. 10.1172/JCI65268 23426181
69. Mancini S. J., Boyd D., Katwan O. J., Strembitska A., Almabrouk T. A., Kennedy S., et al. (2018). Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. Sci. Rep. 8:5276. 10.1038/s41598-018-23420-4 29588466
70. Mentzer R. M., Bartels C., Bolli R., Boyce S., Buckberg G. D., Chaitman B., et al. (2008). Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. Ann. Thorac. Surg. 85 1261–1270. 10.1016/j.athoracsur.2007.10.054 18355507
71. Miki T., Yuda S., Kouzu H., Miura T., (2013). Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail. Rev. 18 149–166. 10.1007/s10741-012-9313-3 22453289
72. Munasinghe P. E., Riu F., Dixit P., Edamatsu M., Saxena P., Hamer N. S. J., et al. (2016). Type-2 diabetes increases autophagy in the human heart through promotion of Beclin-1 mediated pathway. Int. J. Cardiol. 202 13–20. 10.1016/j.ijcard.2015.08.111 26386349
73. + efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38 1142–1153. 10.1016/j.immuni.2013.05.016 23809161
74. Münzel T., Gori T., Keaney J. F., Maack C., Daiber A., (2015). Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications. Eur. Heart J. 36 2555–2564. 10.1093/eurheartj/ehv305 26142467
75. Murphy E., Eisner D. A., (2009). Regulation of intracellular and mitochondrial sodium in health and disease. Circ. Res. 104 292–303. 10.1161/CIRCRESAHA.108.189050 19213964
76. Mustroph J., Wagemann O., Lücht C. M., Trum M., Hammer K. P., Martin C., et al. (2018). Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes. ESC Hear. Fail. 5 642–648. 10.1002/ehf2.12336 30117720
77. Neal B., Perkovic V., Mahaffey K. W., de Zeeuw D., Fulcher G., Erondu N., et al. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377 644–657. 10.1056/NEJMoa1611925 28605608
78. + levels in right atrial myocardium of patients with atrial fibrillation. Circ. Res. 106 1134–1144. 10.1161/CIRCRESAHA.109.203836 20056922
79. Neubauer S., (2007). The failing heart — an engine out of fuel. N. Engl. J. Med. 356 1140–1151. 10.1056/NEJMra063052 17360992
80. Oelze M., Kröller-Schön S., Welschof P., Jansen T., Hausding M., Mikhed Y., et al. (2014). The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One 9:e112394. 10.1371/journal.pone.0112394 25402275
81. Packer M., (2017). Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure. Circulation 136 1548–1559. 10.1161/CIRCULATIONAHA.117.030418 29038209
82. Paulus W. J., Tschöpe C., (2013). A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 62 263–271. 10.1016/j.jacc.2013.02.092 23684677
83. Pogwizd S. M., Sipido K. R., Verdonck F., Bers D. M., (2003). Intracellular Na in animal models of hypertrophy and heart failure: contractile function and arrhythmogenesis. Cardiovasc. Res. 57 887–896. 10.1016/S0008-6363(02)00735-6 12650867
84. Riehle C., Abel E., (2016). Insulin signaling and heart failure. Circ. Res. 118 1151–1169. 10.1161/CIRCRESAHA.116.306206 27034277
85. + mobilization. Vascul. Pharmacol. 58 319–325. 10.1016/j.vph.2012.11.004 23268360
86. Scheen A. J., (2014). Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin. Drug Metab. Toxicol. 10 647–663. 10.1517/17425255.2014.873788 24387329
87. Sena C. M., Pereira A. M., Seiça R., (2013). Endothelial dysfunction - A major mediator of diabetic vascular disease. Biochim. Biophys. Acta 1832 2216–2231. 10.1016/j.bbadis.2013.08.006 23994612
88. Shah M. S., Brownlee M., (2017). Molecular and cellular mechanisms of cardiovascular disorders in diabetes. Circ. Res. 118 1808–1829. 10.1161/CIRCRESAHA.116.306923.Molecular
89. Sharma A., Tate M., Mathew G., Vince J. E., Ritchie R. H., De Haan J. B., (2018). Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications: therapeutic implications. Front. Physiol. 9:114. 10.3389/fphys.2018.00114 29515457
90. Steven S., Oelze M., Hanf A., Kröller-Schön S., Kashani F., Roohani S., et al. (2017). The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 13 370–385. 10.1016/j.redox.2017.06.009 28667906
91. Suzuki M., Honda K., Fukazawa M., Ozawa K., Hagita H., Kawai T., et al. (2012). Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J. Pharmacol. Exp. Ther. 341 692–701. 10.1124/jpet.112.191593 22410641
92. Tanajak P., Sa-nguanmoo P., Sivasinprasasn S., Thummasorn S., Siri-Angkul N., Chattipakorn S. C., et al. (2018). Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury. J. Endocrinol. 236 69–84. 10.1530/JOE-17-0457 29142025
93. + exchange blockers EIPA, cariporide and eniporide. Mol. Cell. Biochem. 250 47–54. 10.1023/A:1024985931797
94. Théroux P., Chaitman B. R., Danchin N., Erhardt L., Meinertz T., Schroeder J. S., et al. (2000). Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. main results of the GUARDIAN trial. Circulation 102 3032–3038. 10.1161/01.CIR.102.25.3032 11120691
95. Tian R., Musi N., D’Agostino J., Hirshman M. F., Goodyear L. J., (2001). Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 104 1664–1669. 10.1161/hc4001.097183 11581146
96. + and vasodilation. Diabetologia 61 722–726. 10.1007/s00125-017-4509-7 29197997
97. Uthman L., Homayr A., Hollmann M. W., Zuurbier C. J., Weber N. C., (2018b). Administration of SGLT2 inhibitor empagliflozin against TNF-α induced endothelial dysfunction in human venous and arterial endothelial cells. FASEB J. 32:569.4.
98. Uthman L., Nederlof R., Eerbeek O., Baartscheer A., Buchholtz N., Coronel R., et al. (2018c). Empagliflozin effects on ischemic contracture and I/R injury in isolated mouse hearts perfused with or without insulin. FASEB J. 32:lb292.
99. Van Heerebeek L., Hamdani N., Handoko M. L., Falcao-Pires I., Musters R. J., Kupreishvili K., et al. (2008). Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117 43–51. 10.1161/CIRCULATIONAHA.107.728550 18071071
100. Van Steenbergen A., Balteau M., Ginion A., Ferté L., Battault S., Ravenstein C. D., et al. (2017). Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart. Sci. Rep. 7:41166. 10.1038/srep41166 28128227
101. Varma U., Koutsifeli P., Benson V. L., Mellor K. M., Delbridge L. M. D., (2018). Molecular mechanisms of cardiac pathology in diabetes – Experimental insights. Biochim. Biophys. Acta 1864 1949–1959. 10.1016/j.bbadis.2017.10.035 29109032
102. Vornov J. J., Thomas A. G., Jo D., (1996). Protective effects of extracellular acidosis and blockade of sodium/hydrogen ion exchange during recovery from metabolic inhibition in neuronal tissue culture. J. Neurochem. 67 2379–2389. 10.1046/j.1471-4159.1996.67062379.x 8931470
103. +-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch. Eur. J. Physiol. 467 1881–1898. 10.1007/s00424-014-1619-7 25304002
104. Wan Z., Wen W., Ren K., Zhou D., Liu J., Wu Y., et al. (2018). Involvement of NLRP3 inflammasome in the impacts of sodium and potassium on insulin resistance in normotensive Asians. Br. J. Nutr. 119 228–237. 10.1017/S0007114517002926 29359681
105. + exchanger is required for hyperglycaemia- induced endothelial dysfunction via calcium-dependent calpain. Cardiovasc. Res. 80 255–262. 10.1093/cvr/cvn179 18591204
106. WHO (2012). Guideline: Sodium Intake for Adults and Children. Geneva: World Health Organization.
107. Ye Y., Bajaj M., Yang H. C., Perez-Polo J. R., Birnbaum Y., (2017). SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc. Drugs Ther. 31 119–132. 10.1007/s10557-017-6725-2 28447181
108. + exchanger activity and expression in human ventricular myocardium. J. Am. Coll. Cardiol. 36 534–540. 10.1016/S0735-1097(00)00730-0
109. + exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction11This manuscript is dedicated to the memory of Karl-Ludwig Neuhaus (1944–2000). J. Am. Coll. Cardiol. 38 E1644–E1650. 10.1016/S0735-1097(01)01608-4
110. Zhou H., Wang S., Zhu P., Hu S., Chen Y., Ren J., (2018). Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol. 15 335–346. 10.1016/j.redox.2017.12.019 29306791
111. +/glucose cotransporter 1 (SGLT1). J. Cell. Biochem. 90 339–346. 10.1002/jcb.10631 14505350
112. Zinman B., Wanner C., Lachin J. M., Fitchett D., Bluhmki E., Hantel S., et al. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373 2117–2128. 10.1056/NEJMoa1504720 26378978